ATG003 Completed Phase 2 Trials for Age - Related Macular Degeneration (AMD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00607750Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF